Abbott Laboratories (ABT:US) and AbbVie Inc. will face lawsuits combined in one Chicago court over claims they hid the risks of using the testosterone-replacement drug AndroGel.
Abbott and AbbVie, a company Abbott spun off last year, are both based in the Chicago area and “a significant number” of AndroGel suits already are pending before U.S. District Judge Matthew Kennelly there, a panel of judges said yesterday it its decision to consolidate the cases. Kennelly will oversee pretrial information exchanges as part of the consolidation.
The decision to collect the AndroGel cases before Kennelly comes after the U.S. Food and Drug Administration said it will re-examine the safety of testosterone-replacement drugs after studies showed the medicine posed an increased risk of heart attack and stroke.
The market for testosterone replacement drugs, which include AndroGel and Axiron, made by Eli Lilly & Co. (LLY:US), is worth $1.6 billion annually. The consolidation will encompass all lawsuits against makers of testosterone-replacement pills, the panel said in its order.
“Abbott separated its research-based pharmaceutical business into a new public biopharmaceutical company called AbbVie in January 2013,” Scott Stoffel, an Abbott spokesman, said in an e-mailed statement. “With the separation, the U.S. commercial rights and associated responsibilities for AndroGel passed to AbbVie.”
Dirk Van Eeden, a spokesman for North Chicago, Illinois-based AbbVie, said the company supported the consolidation “in the interest of consistency and efficiency.”
While only about 45 AndroGel cases have been filed in federal courts in the U.S. so far, Kennelly may wind up overseeing thousands once suits against other manufacturers are filed and consolidated with the ones against Abbott and AbbVie, the Panel on Multidistrict Litigation said.
Abbott and AbbVie have been accused in patient suits of starting an $80 million marketing campaign in 2012 to promote AndroGel for a condition known as Low T. Television ads encouraged men complaining of low energy and lack of sexual drive to take the testosterone-boosting medicine, according to the plaintiffs.
Other companies that sell testosterone-boosting medicines, such as Pfizer Inc. (PFE:US) and Actavis Inc. (ACT:US), opposed consolidating cases over their products with the AndroGel suits against Abbott and AbbVie, the panel said.
The panel said the lawsuits involve common questions of fact and centralizing them in Chicago will promote efficiency.
Putting all the cases before Kennelly will help speed the litigation, said Alex MacDonald, a Boston-based plaintiffs’ lawyer representing patients who took the medicines. MacDonald sued Abbott and AbbVie in federal court in Boston last month on behalf of a former AndroGel user who suffered a stroke while taking the testosterone supplement.
“Testosterone supplements are a lifestyle drug that treat a contrived condition by subjecting men to deadly risks of heart attacks and strokes,” MacDonald said yesterday in an e-mail.
The case is In Re AndroGel Products Liability Litigation, MDL No. 2545, U.S. District Court, Northern District of Illinois (Chicago).
To contact the reporters on this story: Jef Feeley in Wilmington, Delaware at email@example.com; Andrew Harris in federal court in Chicago at firstname.lastname@example.org
To contact the editors responsible for this story: Michael Hytha at email@example.com Andrew Dunn